What is clock.bio?
clock.bio is a biotechnology company founded on the principle of increasing human healthspan. The company is dedicated to decoding the natural rejuvenation processes within human cells to develop novel therapeutic interventions for age-related diseases. Structured as a collaborative partnership between scientists and experienced operators, clock.bio is driven by a shared ethical commitment to making rejuvenation treatments universally accessible. Their scientific approach focuses on understanding and harnessing cellular rejuvenation mechanisms to combat the effects of aging.
How much funding has clock.bio raised?
clock.bio has raised a total of $5.3M across 1 funding round:
Angel/Seed
$5.3M
Angel/Seed (2024): $5.3M with participation from LocalGlobe, BlueYard Capital, and Onsight Ventures
Key Investors in clock.bio
LocalGlobe
LocalGlobe is an investment firm that typically backs early-stage companies, focusing on disruptive technologies and innovative business models.
BlueYard Capital
BlueYard Capital is a venture capital firm that invests in innovative technologies across various sectors, including computation, engineering, biology, and cryptocurrency. The firm focuses on supporting founders who are building solutions that contribute to a better future while addressing significant global challenges.
Onsight Ventures
Onsight Ventures is a deep tech investment fund based in Innsbruck that focuses on empowering European founders to become global leaders in technology-driven sectors. The firm invests in early-stage companies with significant scaling potential, covering areas such as gene therapy, quantum computing, and synthetic biology.
What's next for clock.bio?
With the recent major strategic investment, clock.bio is poised to accelerate its research and development efforts. This capital will likely fuel the advancement of their novel treatments aimed at preventing and treating age-related diseases by targeting cellular rejuvenation pathways. The company's focus on accessibility suggests a strategy that may involve broad-scale clinical trials and strategic partnerships to ensure their therapies reach a global population. clock.bio's enterprise-level funding context indicates a transition towards scaling operations and potentially moving into later-stage development or commercialization phases.
See full clock.bio company page
